Fig. 1

Characterization of circMED13L_012 and its expression pattern in NSCLC samples. a Schematic illustration of chromosomal location of circMED13L_012. b qRT-PCR analysis of circMED13L_012 and MED13L mRNA level in A549 cells which were treated by RNase or negative control respectively. c qRT-PCR analysis of circMED13L_012 and MED13L mRNA level in A549 cells which were treated by actinomycin-D or negative control respectively for different period of time (0 h, 6 h, 12 h, 18 h, 24 h). d relative expression level detection of circMED13L_012, MED13L, GAPDH and U6 in cytoplasmic or nuclear region of A549 cells. e, f Comparison of circMED13L_012 and MED13L expression level between NSCLC and matched normal lung tissues. g Comparison of circMED13L_012 expression level between early stage (T1, T2) and advanced stage (T3, T4) NSCLC tumors samples. h Comparison of circMED13L_012 expression level in NSCLC tumor samples with or without lymph node metastasis. i Comparison of circMED13L_012 expression level in NSCLC tumor samples with or without distal organ metastatic disease. j Comparison of circMED13L_012 expression level among different NSCLC cell lines (NCI-H1975, NCI-H1299, A549, SPC-A-1) and human normal bronchial epithelial cell line HNBE